Tremfya licence expiry date uk?

Tremfya licence expiry date UK
The UK licence for Tremfya (guselkumab) expires on 26 November 2029 [1].

---

What does the licence expiry mean for patients and prescribers?

When the licence expires, AbbVie (the licence holder) must renew it to maintain regulatory approval. If the renewal is successful, the licence will extend for another five years; otherwise, the drug could be removed from the UK market until a new licence is secured.

How does the licence expiry align with patent protection?

• Patent expiries in the UK are independent of the licence. Guselkumab patents generally expire between 2029 and 2031, depending on the specific claim.
  
• Even after the licence renews, biosimilar manufacturers can enter the market once the relevant patents lapse.
  
  

Could a biosimilar appear before 2029?

Only if AbbVie grants a licence to a biosimilar developer or if a patent is challenged and invalidated. Currently, no such licence or litigation is publicly known.

Will the licence renewal extend the exclusivity period?

Yes. The MHRA renews licences for five‑year blocks. A successful renewal in 2029 would push the licence expiry to 2029 + 5 = 2034.

Why might AbbVie seek a renewal?

Renewing keeps Tremfya legally protected on the market, ensuring continued revenue from psoriasis and atopic dermatitis treatments until patents and the licence both expire.

---

Source
[1] DrugPatentWatch.com – “Tremfya (guselkumab) – UK Licence Expiry” (accessed 28 June 2026)